{"id":"guanfacine-tenex","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Dry mouth"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL862","moleculeType":"Small molecule","molecularWeight":"246.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively binding to alpha-2A adrenergic receptors in the prefrontal cortex and other brain regions, guanfacine decreases norepinephrine signaling, which improves attention, impulse control, and reduces hyperactivity. This mechanism makes it particularly useful for conditions characterized by prefrontal cortex dysfunction, such as ADHD and hypertension.","oneSentence":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:41.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06408246","phase":"PHASE2","title":"ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-03-03","conditions":"Depression","enrollment":162},{"nctId":"NCT03764098","phase":"PHASE2","title":"Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders","status":"RECRUITING","sponsor":"Yale University","startDate":"2020-08-10","conditions":"Alcohol Use","enrollment":160},{"nctId":"NCT04742673","phase":"PHASE2","title":"Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-05-04","conditions":"Critical Illness, Delirium, Cognitive Impairment","enrollment":46},{"nctId":"NCT06042257","phase":"PHASE2","title":"Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)","status":"TERMINATED","sponsor":"Rachel G. Greenberg, MD, MB, MHS","startDate":"2024-12-09","conditions":"Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome","enrollment":3},{"nctId":"NCT07300956","phase":"PHASE4","title":"Treating Young Children With Attention Deficit Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":370},{"nctId":"NCT02192398","phase":"NA","title":"Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2014-09","conditions":"Chronic Pain","enrollment":120},{"nctId":"NCT01681264","phase":"PHASE4","title":"Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2014-09","conditions":"Chronic Pain","enrollment":200},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT06629259","phase":"PHASE2","title":"Guanfacine for Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-09-01","conditions":"Alcohol Use Disorder","enrollment":200},{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT06580041","phase":"PHASE4","title":"Precision Care for Major Depressive Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2024-11-12","conditions":"Major Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":150},{"nctId":"NCT02141113","phase":"PHASE4","title":"Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).","status":"COMPLETED","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2012-11","conditions":"Adult Attention-Deficit Hyperactivity Disorder","enrollment":26},{"nctId":"NCT06642181","phase":"PHASE1","title":"Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-07-15","conditions":"Mindfulness, Guanfacine, Opioid Use Disorder","enrollment":224},{"nctId":"NCT05957848","phase":"PHASE2","title":"Guanfacine Extended-release for Adolescents With Cannabis Use","status":"RECRUITING","sponsor":"Orygen","startDate":"2023-07-27","conditions":"Cannabis Use Disorder","enrollment":100},{"nctId":"NCT04198116","phase":"PHASE2","title":"Combining Varenicline and Guanfacine for Smoking Cessation","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-11-01","conditions":"Smoking Cessation","enrollment":165},{"nctId":"NCT05273567","phase":"PHASE2","title":"A Trial of Guanfacine-er for Cannabis Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2022-06-01","conditions":"Cannabis Use","enrollment":22},{"nctId":"NCT04113551","phase":"","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":17418},{"nctId":"NCT05710627","phase":"NA","title":"Evaluation of TENEX for Greater Trochanteric Pain Syndrome (GTPS)","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2025-03-11","conditions":"Greater Trochanteric Pain Syndrome","enrollment":150},{"nctId":"NCT04578886","phase":"PHASE3","title":"The Effect of Guanfacine on Delirium in Critically Ill Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-11-23","conditions":"Delirium","enrollment":100},{"nctId":"NCT03865940","phase":"PHASE2","title":"Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-04","conditions":"Trigeminal Neuralgia","enrollment":37},{"nctId":"NCT04181736","phase":"PHASE4","title":"The BIomarker Guided (BIG) Study for Depression","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-09-14","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05757739","phase":"","title":"Randomized Controlled Trial (RCT) of Open Debridement Versus Tenex","status":"RECRUITING","sponsor":"Virtua Health, Inc.","startDate":"2023-02-09","conditions":"Orthopedic Devices Associated With Misadventures","enrollment":90},{"nctId":"NCT04737512","phase":"EARLY_PHASE1","title":"Mindfulness-Based ADHD Treatment for Children: a Feasibility Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":68},{"nctId":"NCT05657860","phase":"PHASE4","title":"Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Maimonides Medical Center","startDate":"2020-12-17","conditions":"Prader-Willi Syndrome, Aggression, Self-Injurious Behavior","enrollment":15},{"nctId":"NCT03137082","phase":"PHASE1, PHASE2","title":"Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-07-12","conditions":"Alcohol Abstinence","enrollment":32},{"nctId":"NCT04549051","phase":"NA","title":"Percutaneous Interruption of the Coracohumeral Ligament for the Treatment of Frozen Shoulder","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2020-11-17","conditions":"Adhesive Capsulitis","enrollment":46},{"nctId":"NCT03116126","phase":"PHASE3","title":"Noradrenergic Add-on Therapy With Guanfacine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imperial College London","startDate":"2019-01-04","conditions":"Alzheimer Disease","enrollment":148},{"nctId":"NCT03980184","phase":"PHASE2","title":"Guanfacine to Improve Substance Use Outcomes in Women","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-01","conditions":"Substance Use Disorders","enrollment":74},{"nctId":"NCT06137222","phase":"NA","title":"Prospective, Multicenter, RCT of the Tenex Ultrasound System","status":"UNKNOWN","sponsor":"Tenex Health Inc.","startDate":"2023-12-04","conditions":"Diabetic Foot Ulcer","enrollment":148},{"nctId":"NCT02136147","phase":"","title":"ADHD Medication and Predictors of Treatment Outcome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-06","conditions":"Attention Deficit Disorder With Hyperactivity (ADHD)","enrollment":632},{"nctId":"NCT05870605","phase":"","title":"Drug Use Study With Intuniv® in European Countries","status":"COMPLETED","sponsor":"Shire","startDate":"2018-11-15","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":5000},{"nctId":"NCT02259517","phase":"NA","title":"An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":38},{"nctId":"NCT04384809","phase":"PHASE4","title":"Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2023-01-01","conditions":"Lateral Epicondylitis (Tennis Elbow)","enrollment":""},{"nctId":"NCT03333668","phase":"NA","title":"Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents","status":"UNKNOWN","sponsor":"King's College London","startDate":"2018-10-01","conditions":"ADHD","enrollment":20},{"nctId":"NCT04299802","phase":"NA","title":"Percutaneous Ultrasonic Tenotomy Versus Platelet Rich Plasma for Gluteal Tendinopathy","status":"WITHDRAWN","sponsor":"Andrews Research & Education Foundation","startDate":"2020-02-20","conditions":"Gluteal Tendinitis, Trochanteric Bursitis, Tendinopathy","enrollment":""},{"nctId":"NCT00773357","phase":"PHASE2","title":"Modeling Stress-precipitated Smoking Behavior for Medication Development","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-10","conditions":"Smoking","enrollment":100},{"nctId":"NCT05305404","phase":"EARLY_PHASE1","title":"Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving","status":"UNKNOWN","sponsor":"Stony Brook University","startDate":"2022-03-11","conditions":"Alcohol Use Disorder","enrollment":70},{"nctId":"NCT02051309","phase":"PHASE2","title":"Guanfacine Clinical Trial for Smoking Cessation","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03","conditions":"Smoking Cessation","enrollment":121},{"nctId":"NCT04866030","phase":"","title":"Drug Use Study With Intuniv® in Australia","status":"COMPLETED","sponsor":"Shire","startDate":"2019-03-11","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":100},{"nctId":"NCT01547000","phase":"PHASE4","title":"Guanfacine in Children With Tic Disorders","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-04","conditions":"Tourette Disorder, Tourette Syndrome","enrollment":34},{"nctId":"NCT00429273","phase":"PHASE4","title":"Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":212},{"nctId":"NCT02164422","phase":"PHASE2","title":"Does Guanfacine Attenuate Stress-Induced Drinking?","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-06","conditions":"Alcohol Drinking","enrollment":70},{"nctId":"NCT01244490","phase":"PHASE3","title":"Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-01-17","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":338},{"nctId":"NCT01081132","phase":"PHASE3","title":"Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl","status":"COMPLETED","sponsor":"Shire","startDate":"2011-09-19","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":314},{"nctId":"NCT01500694","phase":"PHASE3","title":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-20","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":215},{"nctId":"NCT00901576","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-05-18","conditions":"Healthy","enrollment":38},{"nctId":"NCT00734578","phase":"PHASE3","title":"Efficacy and Safety of SPD503 in Combination With Psychostimulants","status":"COMPLETED","sponsor":"Shire","startDate":"2008-09-02","conditions":"ADHD","enrollment":461},{"nctId":"NCT00919867","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-06-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT00367835","phase":"PHASE3","title":"SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2006-12-04","conditions":"ADHD","enrollment":217},{"nctId":"NCT01081145","phase":"PHASE3","title":"Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2010-05-11","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":528},{"nctId":"NCT00672984","phase":"PHASE1","title":"Guanfacine Immediate-release Electrocardiogram Results (QTc) Study","status":"COMPLETED","sponsor":"Shire","startDate":"2008-04-18","conditions":"Healthy Volunteers","enrollment":83},{"nctId":"NCT00151996","phase":"PHASE2","title":"Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2004-08-16","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":75},{"nctId":"NCT00152009","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2003-01-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":345},{"nctId":"NCT01470469","phase":"PHASE2","title":"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-01-04","conditions":"Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social","enrollment":83},{"nctId":"NCT00150618","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2004-03-30","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":324},{"nctId":"NCT00150592","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2005-05-12","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":182},{"nctId":"NCT00997984","phase":"PHASE3","title":"Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)","status":"COMPLETED","sponsor":"Shire","startDate":"2009-11-17","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":340},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03258476","phase":"PHASE4","title":"Guanfacine Extended Release and Mindfulness Skills Therapy","status":"WITHDRAWN","sponsor":"UConn Health","startDate":"2019-03-01","conditions":"Stress Disorder","enrollment":""},{"nctId":"NCT02699125","phase":"PHASE4","title":"Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-01","conditions":"Obstructive Sleep Apnea","enrollment":41},{"nctId":"NCT04066088","phase":"PHASE4","title":"Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2019-12-01","conditions":"Prader-Willi Syndrome","enrollment":""},{"nctId":"NCT04016207","phase":"","title":"Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2020-04-01","conditions":"Affective Dysregulation","enrollment":40},{"nctId":"NCT01238575","phase":"PHASE4","title":"Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-12","conditions":"Pervasive Development Disorders","enrollment":62},{"nctId":"NCT01904526","phase":"PHASE2","title":"PK/PD Comparison of Guanfacine ER and IR","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-07","conditions":"Smoking","enrollment":5},{"nctId":"NCT00955253","phase":"PHASE2","title":"Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-04","conditions":"Stroke, Hemispatial Neglect","enrollment":13},{"nctId":"NCT01467999","phase":"PHASE1","title":"Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2012-02","conditions":"Cannabis Dependence","enrollment":22},{"nctId":"NCT02882854","phase":"NA","title":"Guanfacine for PONV and Pain After Sinus Surgery","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-11","conditions":"Postoperative Nausea and Vomiting, Pain, Postoperative","enrollment":84},{"nctId":"NCT03662763","phase":"PHASE3","title":"Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Attention Deficit Disorder","enrollment":12},{"nctId":"NCT02788851","phase":"NA","title":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT02048241","phase":"PHASE4","title":"Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-07","conditions":"Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder","enrollment":11},{"nctId":"NCT00613015","phase":"PHASE2","title":"Stress and Medication Effects on Cocaine Cue Reactivity","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-05","conditions":"Cocaine Related Disorders","enrollment":109},{"nctId":"NCT01709695","phase":"PHASE4","title":"Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2011-03","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":27},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01600885","phase":"NA","title":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-08","conditions":"NMDA Receptor Function","enrollment":16},{"nctId":"NCT00109642","phase":"","title":"The Role of Norepinephrine in Emotional Processing","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2005-04-26","conditions":"Psychopathy, Mental Disorders","enrollment":216},{"nctId":"NCT02204410","phase":"PHASE4","title":"Omega-3 Supplementation to ADHD Medication in Children","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-07","conditions":"Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation","enrollment":21},{"nctId":"NCT01133847","phase":"PHASE4","title":"Interventions for Children With Attention and Reading Disorders","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-11","conditions":"Attention Deficit Hyperactivity Disorder, Reading Disabilities","enrollment":222},{"nctId":"NCT02524899","phase":"PHASE2","title":"CRT-Guanfacine for SPD","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-01","conditions":"Schizotypal Personality Disorder, SPD","enrollment":45},{"nctId":"NCT00353379","phase":"PHASE4","title":"Pharmacology of Cognition in Schizotypal Personality Disorder","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"1995-09","conditions":"Schizotypal Personality Disorder, Personality Disorders","enrollment":29},{"nctId":"NCT00585754","phase":"PHASE1","title":"Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-04","conditions":"Cocaine Dependent, Alcohol Dependent","enrollment":75},{"nctId":"NCT01985581","phase":"PHASE4","title":"Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD","status":"COMPLETED","sponsor":"JPM van Stralen Medicine Professional","startDate":"2013-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":50},{"nctId":"NCT00935493","phase":"NA","title":"Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-06","conditions":"Cognitive Aging","enrollment":154},{"nctId":"NCT01156051","phase":"PHASE4","title":"Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia","status":"TERMINATED","sponsor":"Children's Specialized Hospital","startDate":"2010-06","conditions":"Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia","enrollment":29},{"nctId":"NCT01177306","phase":"PHASE4","title":"Inuniv and Working Memory","status":"COMPLETED","sponsor":"Lori A. Schweickert, MD","startDate":"2010-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":18},{"nctId":"NCT01146002","phase":"PHASE4","title":"Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine","status":"COMPLETED","sponsor":"Neurology Group of Bergen County, P.A.","startDate":"2010-06","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":30},{"nctId":"NCT00389779","phase":"PHASE3","title":"DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-09","conditions":"Hypertension","enrollment":849},{"nctId":"NCT00389675","phase":"PHASE3","title":"DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2007-05","conditions":"Hypertension","enrollment":661},{"nctId":"NCT01069523","phase":"PHASE4","title":"Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2010-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":42},{"nctId":"NCT00025779","phase":"NA","title":"Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2001-10","conditions":"Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders","enrollment":60},{"nctId":"NCT00018603","phase":"PHASE1","title":"Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1999-11","conditions":"Post-Traumatic Stress Disorder","enrollment":""},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00469664","phase":"PHASE4","title":"Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia","status":"UNKNOWN","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2000-02","conditions":"Schizophrenia, Schizoaffective Disorder, Cognitive Impairment","enrollment":50},{"nctId":"NCT00358969","phase":"NA","title":"Guanfacine to Treat Borderline Personality Disorder","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2006-07","conditions":"Borderline Personality Disorder","enrollment":""},{"nctId":"NCT00004376","phase":"PHASE3","title":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1994-09","conditions":"Tourette Syndrome","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Guanfacine/Tenex","genericName":"Guanfacine/Tenex","companyName":"Research Foundation for Mental Hygiene, Inc.","companyId":"research-foundation-for-mental-hygiene-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}